26264 Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices 

Place: W Chicago—Lakeshore, 644 North 

Lake Shore Drive, Chicago, IL 60611. 

Contact Person: Jacinta Bronte-Tinkew, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3164, 

MSC 7770, Bethesda, MD 20892, (301) 435– 

1503, rontetinkewjm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; ARRA: 

Neurobiology of Motivated Behavior 

Competitive Revisions. 

Date: June 3, 2010. 

Time: 4 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz Carlton Hotel, 1150 22nd Street, 

NW., Washington, DC 20037. 

Contact Person: Edwin C. Clayton, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5180, 

MSC 7844, Bethesda, MD 20892, 301–408– 

9041, claytone@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; ARRA: 

Pathophysiological Basis of Mental Disorders 

and Addictions Competitive Revisions. 

Date: June 3, 2010. 

Time: 4 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Fairmont Washington, DC, 2401 

M Street, NW., Washington, DC 20037. 

Contact Person: Boris P Sokolov, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217A, 

MSC 7846, Bethesda, MD 20892, 301–408– 

9115, bsokolov@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; ARRA: 

Sensorimotor Integration Study Section 

Competitive Revisions. 

Date: June 3, 2010. 

Time: 5 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Palomar, 2121 P Street, NW., 

Washington, DC 20037. 

Contact Person: John Bishop, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5182, 

MSC 7844, Bethesda, MD 20892, (301) 408– 

9664, bishopj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; SRO 

Conflict: Central Visual Processing 

Competitive Revisions. 

Date: June 3, 2010. 

Time: 5 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Palomar, 2121 P Street, NW., 

Washington, DC 20037. 

Contact Person: Christine L. Melchior, 

PhD, Chief and Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 5176, MSC 7844, Bethesda, MD 20892, 

(301) 435–1713, melchioc@csr.nih.gov. 

Name of Committee: Surgical Sciences, 

Biomedical Imaging and Bioengineering 

Integrated Review Group; Medical Imaging 

Study Section. 

Date: June 3–4, 2010. 

Time: 7 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Little America Hotel, 500 South 

Main Street, Salt Lake City, UT 84101. 

Contact Person: Xiang-Ning Li, MD, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5112, 

MSC 7854, Bethesda, MD 20892, 301–435– 

1744, lixiang@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; ARRA: 

Behavioral Medicine, Interventions and 

Outcomes Competitive Revisions. 

Date: June 3, 2010. 

Time: 12 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: W Chicago—Lakeshore, 644 North 

Lake Shore Drive, Chicago, IL 60611. 

Contact Person: Lee S. Mann, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3186, 

MSC 7848, Bethesda, MD 20892, 301–435– 

0677, mannl@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: May 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–11045 Filed 5–10–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; ITVC 

Member Conflicts. 

Date: June 11, 2010. 

Time: 10:30 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Enid Light, PhD, Scientific 

Review Officer, Division of Extramural 

Activities, National Institute of Mental 

Health, NIH, Neuroscience Center, 6001 

Executive Blvd., Room 6132, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–0322, 

elight@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: May 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–11044 Filed 5–10–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Dermatologic and Ophthalmic Drugs 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Dermatologic 

and Ophthalmic Drugs Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on June 28, 2010, from 8 a.m. to 5 

p.m. 

Location: Sheraton Washington North 

Hotel, The Ballroom, 4095 Powder Mill 

Rd, Beltsville, MD. The hotel telephone 

number is 301–937–4422. 

Contact Person: Yvette Waples, c/o 

Melanie Whelan, Food and Drug 

Administration, 10903 New Hampshire 

Ave., WO51– 6100, Silver Spring, MD 

20993–0002, FAX: 301–847–8737 (to 

reach by telephone before June 8, 2010, 

please call 301–827–7001; to reach by 

telephone after June 8, 2010, please call 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices 26265 

301–796–9001, yvette.waples@ 

fda.hhs.gov) or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512534. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On June 28, 2010, the 

committee will discuss new drug 

application (NDA) 22–340, voclosporin 

10-milligram capsules, by Lux 

Biosciences, Inc. The proposed 

indication for this new drug product is 

treatment of noninfectious uveitis 

involving the posterior or intermediate 

segments of the eye. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before June 14, 2010. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before June 4, 2010. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by June 7, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Yvette 

Waples at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/AboutAdvisory

Committees/ucm111462.htm for 

procedures on public conduct during 

advisory committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: May 5, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–11039 Filed 5–10–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Pediatric Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Pediatric 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on Monday, June 21, 2010, from 9 

a.m. to 5 p.m. 

Location: Bethesda Marriott Hotel, 

Congressional Ballroom, 5151 Pooks 

Hill Rd., Bethesda, MD. 20814. 

Contact Person: Doreen Kezer, Office 

of Science and Health Coordination, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 32, rm. 

4254, Silver Spring, MD 20993–0002, 

301–796–8524, e-mail: 

Doreen.Kezer@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732310001. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On Monday, June 21, the 

Pediatric Advisory Committee will meet 

to discuss pediatric-focused safety 

reviews, as mandated by the Best 

Pharmaceuticals for Children Act and 

the Pediatric Research Equity Act, for 

Kogenate FS (antihemophilic factor 

(recombinant)), Casodex (bicalutamide), 

Apidra (insulin glulisine [rDNA]), 

NovoLog (insulin aspart [rDNA]), 

Arimidex (anastrozole), Desmopressin 

Acetate, Prevacid (lansoprazole), 

Nexium (esomeprazole magnesium), 

Aciphex (rabeprazole sodium), Prilosec 

(omeprazole), OraVerse (phentolamine 

mesylate), Zemuron (rocuronium 

bromide). The committee will also 

receive a followup presentation on 

Suprane (desflurane). 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before June 7, 2010. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 


emcdonald on DSK2BSOYB1PROD with NOTICES